Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Resectable Pancreatic Cancer 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 280Specimen Handling 266pembrolizumab 244Cyclophosphamide 224Radiotherapy 220Nivolumab 179Cisplatin 166Biopsy 158Carboplatin 150Radiosurgery 144fludarabine 124Blood Specimen Collection 121Surveys and Questionnaires 117venetoclax 115Gemcitabine 115Paclitaxel 114Standard of Care 104Dexamethasone 103Rituximab 91Radiation 90Oxaliplatin 87Bevacizumab 87Ipilimumab 84Drug Therapy 84Cytarabine 84Doxorubicin 81durvalumab 77Capecitabine 77Fluorouracil 69fludarabine phosphate 68

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × paricalcitol × 90 days × Clear all
NCT05365893 2026-05-22

PHL Treatment in Pancreatic Cancer

Fox Chase Cancer Center

Phase EARLY_PHASE1 Active not recruiting
20 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT03415854 2026-05-12

NABPLAGEMD

HonorHealth Research Institute

Phase 2 Completed
34 enrolled 11 charts
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT03138720 2026-04-22

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

HonorHealth Research Institute

Phase 2 Completed
40 enrolled 22 charts
Gastrointestinal

Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡